Docket #0470 Date Filed: 09/21/2026

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,	Case No. 26-10989 (CTG)
Debtor.[1]	Related D.I. 319, 320

CERTIFICATE OF NO OBJECTION REGARDING MOTION OF ASTELLAS GENE THERAPIES, INC. FOR LEAVE TO FILE UNDER SEAL ITS LIMITED OBJECTION TO DEBTOR'S SALE MOTION AND MOTION OF ALEXION PHARMACEUTICALS, INC. FOR LEAVE TO FILE UNDER SEAL ITS LIMITED OBJECTION TO DEBTOR'S SALE MOTION

I, Lawrence J. O'Brien, an attorney with McCarter & English LLP, counsel for Astellas Gene Therapies, Inc. ("Astellas") and Alexion Pharmaceuticals, Inc. ("Alexion"), hereby certify the following:

1. On August 17, 2026, Astellas filed the *Limited Objection of Astellas Gene Therapies, Inc. to Debtor's Proposed Sale of Certain Assets to Stalking Horse Bidder Free and Clear of All Encumbrances* [D.I. 307].

2. On August 17, 2026, Alexion filed the *Limited Objection of Alexion Pharmaceuticals, Inc. to Debtor's Proposed Sale of Certain of its Assets to the Merope Stalking Horse Bidder Free and Clear of all Encumbrances* [D.I. 309].

3. On August 17, 2026, Astellas filed the *Motion of Astellas Gene Therapies, Inc. for Leave to File under Seal its Limited Objection to Debtor's Sale Motion and the Declaration of Abigail V. O'Brient in Support Thereof* [D.I. 319] ("Astellas Sealing Motion").

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94084.

2610989260921000000000006

4. On August 18, 2026, Alexion filed the *Motion of Alexion Pharmaceuticals, Inc. for Leave to File under Seal its Limited Objection to Debtor's Sale Motion and the Declaration of Abigail V. O'Brient in Support Thereof* [D.I. 320] ("Alexion Sealing Motion," and together, the "Motions").

5. As of the date hereof, the undersigned counsel has not been served with any objections or responses to the Motions. A review of the Court's docket indicates that, as of this date, no responses or objections to the Motions have been filed.

WHEREFORE the undersigned, on behalf of the Astellas and Alexion, respectfully requests that the orders granting each of the Motions, attached hereto as **Exhibit A** and **Exhibit B**, be entered at the Court's earliest convenience.

[*Remainder of Page Intentionally Left Blank*]

Date: September 21, 2026

McCARTER & ENGLISH LLP

/s/ Lawrence John O'Brien
Kate Roggio Buck, Esq. (DE #5140)
Lawrence John O'Brien, Esq. (DE #7000)
Renaissance Centre
405 North King Street, 8th Floor
Wilmington, DE 19801
Telephone: (302) 984-6300
Facsimile (302) 984-6399
Email: kbuck@mccarter.com
lobrien@mccarter.com

-and-

COVINGTON & BURLING LLP
Abigail V. O'Brient (admitted *pro hac vice*)
1999 Avenue of the Stars
Los Angeles, CA 90067-4643
Telephone: (424) 332-4800
Email: aobrient@cov.com

-and-

Julia Blackburn (admitted *pro hac vice*)
30 Hudson Yards
New York, NY 10001-2170
Telephone: (212) 841-1000
Email: jblackburn@cov.com

Attorneys for Astellas Gene Therapies, Inc. and Alexion Pharmaceuticals, Inc.

Exhibit A

Order Granting Astellas Sealing Motion

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,	Case No. 26-10989 (CTG)
Debtor.[1]	
	Related D.I. 307, 308

ORDER GRANTING MOTION OF ASTELLAS GENE THERAPIES, INC. FOR LEAVE TO FILE, UNDER SEAL, ITS LIMITED OBJECTION TO DEBTOR'S SALE MOTION AND THE DECLARATION OF ABIGAIL V. O'BRIENT IN SUPPORT THEREOF

Upon the *Motion of Astellas Gene Therapies, Inc. for Leave to File, Under Seal, Its Limited Objection to Debtor's Sale Motion and the Declaration of Abigail V. O'Brient in Support Thereof* (the "Motion to Seal")[2]; and the Court having reviewed the Motion to Seal; and the Court having found that it has jurisdiction to consider the Motion to Seal under 28 U.S.C. §§ 157 and 1334; and having found that this is a core proceeding under 28 U.S.C. § 157(b)(2); and having found that notice of the Motion to Seal was proper and sufficient under the circumstances, and that no other or further notice is required; and the Court having determined that the legal and factual bases set forth in the Motion to Seal establish just cause for the relief granted herein;

IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:

1. The Motion to Seal is granted.

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94804.

[2] Capitalized terms used, but not defined, herein shall have the meanings given to them in the Sale Motion.

2. The Objector is authorized to maintain under seal those portions of the Sealed Documents that contain confidential information regarding the License Agreement and to file redacted versions thereof on the public docket pursuant to Local Rule 9018-1(d).

3. This Court shall retain jurisdiction with respect to all matters arising from and related to the implementation of this Order.

Exhibit B

Order Granting Alexion Sealing Motion

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SANGAMO THERAPEUTICS, INC.,	Case No. 26-10989 (CTG)
Debtor.[1]	
	Related D.I. 309, 310

ORDER GRANTING MOTION OF ALEXION PHARMACEUTICALS, INC. FOR LEAVE TO FILE, UNDER SEAL, ITS LIMITED OBJECTION TO DEBTOR'S SALE MOTION AND THE DECLARATION OF ABIGAIL V. O'BRIENT IN SUPPORT THEREOF

Upon the *Motion of Alexion Pharmaceuticals, Inc. for Leave to File, Under Seal, Its Limited Objection to Debtor's Sale Motion and the Declaration of Abigail V. O'Brient in Support Thereof* (the "Motion to Seal")[2]; and the Court having reviewed the Motion to Seal; and the Court having found that it has jurisdiction to consider the Motion to Seal under 28 U.S.C. §§ 157 and 1334; and having found that this is a core proceeding under 28 U.S.C. § 157(b)(2); and having found that notice of the Motion to Seal was proper and sufficient under the circumstances, and that no other or further notice is required; and the Court having determined that the legal and factual bases set forth in the Motion to Seal establish just cause for the relief granted herein;

IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:

1. The Motion to Seal is granted.

[1] The last four digits of the Debtor's federal tax identification number are 9556. The Debtor's principal office is located at 501 Canal Boulevard, Suite A100, Richmond, CA 94804.

[2] Capitalized terms used, but not defined, herein shall have the meanings given to them in the Motion to Seal.

2. The Objector is authorized to maintain under seal those portions of the Sealed Documents that contain confidential information regarding the License Agreement and to file redacted versions thereof on the public docket pursuant to Local Rule 9018-1(d).

3. This Court shall retain jurisdiction with respect to all matters arising from and related to the implementation of this Order.